<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158756</url>
  </required_header>
  <id_info>
    <org_study_id>104021</org_study_id>
    <nct_id>NCT00158756</nct_id>
  </id_info>
  <brief_title>Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants</brief_title>
  <official_title>A Phase III, Partially Blind, Randomized Study to Evaluate the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB and GSK Biologicals Kft's DTPw-HBV Vaccines as Compared to Concomitant Administration of Commonwealth Serum Laboratory's (CSL's) DTPw (Triple Antigen™) and GSK Biologicals' HBV (Engerix™-B), When Co-administered With GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, to Healthy Infants at 3, 4½ and 6 Months of Age, After a Birth Dose of Hepatitis B Vaccine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      To compare the two formulations of GSK Biologicals' DTPw-HBV vaccine to concomitant
      administration of CSL's DTPw vaccine and GSK Biologicals' HBV with respect to the antibody
      response to the diphtheria antigen after a three-dose primary vaccination course.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study with five groups to receive one of the following vaccination regimens:

      One of the two formulations of GSK Biologicals' DTPw-HBV + GSK Biologicals' HRV One of the
      two formulations of GSK Biologicals' DTPw-HBV + Placebo CSL's DTPw + GSK Biologicals' HBV
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2005</start_date>
  <completion_date type="Actual">November 23, 2006</completion_date>
  <primary_completion_date type="Actual">November 1, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>Seroprotection status (SP) defined vaccinated subjects with antibody concentrations greater than or equal to (≥) 0.1 international units per millitre (IU/mL) as assessed by the Enzyme-linked Immunosorbent Assay (ELISA) or ≥ 0.016 IU/mL by neautralization assay on Vero cells in subjects seronegative for ELISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects for Anti-DT Antibodies as Assessed by ELISA</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>A seroprotected subject is a vaccinated subject with concentrations ≥ 0.1 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects for Anti-Hepatitis B (Anti-HBs) Antibodies</measure>
    <time_frame>At one most post dose 3 [PIII(M4)]</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with antibody concentrations ≥ 10 milli-international units per millilitre (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects With Anti-Bordetella Pertussis (Anti-BPT) Antibody Concentrations ≥ the Established Cut-off Values</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>A seropositive subject was defined as a subject with Anti-BPT antibody concentrations ≥ 15 ELISA units per millilitre (EL.U/mL), as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Response to BPT Antigen</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>Vaccine response (VR) was defined as the appearance of antibodies in subjects seronegative at pre-vaccination and antibody concentrations ≥ the cut-off values post-vaccination in subjects who were seropositive at pre-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects With Anti-rotavirus (Anti-RV) Antibodies Above the Cut-off Values</measure>
    <time_frame>At 2.5 months after dose 2 of Rotarix [PIII(M4)]</time_frame>
    <description>A seropositive subject was defined as a subject with anti-RV antibody concentrations ≥ 20 units per millilitre (U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects for Anti-Tetanus (Anti-T) Antigen</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with anti-T antibody concentrations ≥ the cut-off value of 0.1 international units per millilitre (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects for Anti-Poliovirus Types 1, 2, 3 (Anti-Polio 1, 2, 3)</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with anti-Polio type 1,2 ,3 antibody titers ≥ 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Anti-HBs Antibodies</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>Concentrations of anti-HB, antibodies, expressed as Geometric Mean Concentrations (GMCs), were measured in mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Anti-DT Antibodies</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>Concentrations of anti-DT antibodies, expressed as Geometric Mean Concentrations (GMCs), were measured in IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Anti-T Antibodies</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in international units per millillitre (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Anti-BPT Antibodies</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Anti-RV Antibodies</measure>
    <time_frame>At 2.5 months post dose 2 of Rotarix [PIII(M4)]</time_frame>
    <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Polio Type 1, 2, 3 Antibody Titers</measure>
    <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
    <description>Anti-Polio type 1, 2 and 3 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms</measure>
    <time_frame>During the 8-Day (Days 0-7) follow-up period</time_frame>
    <description>Solicited local symptoms were pain, redness and swelling. Any = occurence of symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest, pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling with a maximum diameter greater than 30 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited General Symptoms</measure>
    <time_frame>During the 8-day period (Days 0-7) post-vaccination</time_frame>
    <description>Assessed solicited general symptoms were diarrhea, drowsiness, fever [defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)], irritability, loss of appetite [loss of appet.] and vomiting. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. Grade 3 loss of appetite = symptoms that prevents eating. Grade 3 diarrhea = ≥ 6 looser than normal stools per (/) day. Grade 3 vomiting = ≥ 3 episodes of vomiting/day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31-day (Days 0-30) follow-up period</time_frame>
    <description>Number of subjects with any unsolicited adverse events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 0 to Month 4</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Tritanrix™-HepB+Rotarix™ Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tritanrix™-HepB+Placebo Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zilbrix™+Rotarix™ Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zilbrix™+Placebo Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Antigen™+Engerix™-B Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tritanrix™-HepB</intervention_name>
    <description>GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.</description>
    <arm_group_label>Tritanrix™-HepB+Rotarix™ Group</arm_group_label>
    <arm_group_label>Tritanrix™-HepB+Placebo Group</arm_group_label>
    <other_name>DTPw-HBV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix™</intervention_name>
    <description>GSK Biologicals' live attenuated human rotavirus vaccine</description>
    <arm_group_label>Tritanrix™-HepB+Rotarix™ Group</arm_group_label>
    <arm_group_label>Zilbrix™+Rotarix™ Group</arm_group_label>
    <other_name>HRV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zilbrix™</intervention_name>
    <description>GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine</description>
    <arm_group_label>Zilbrix™+Placebo Group</arm_group_label>
    <arm_group_label>Zilbrix™+Rotarix™ Group</arm_group_label>
    <other_name>DTPw-HBV Kft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Triple Antigen™</intervention_name>
    <description>Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.</description>
    <arm_group_label>Triple Antigen™+Engerix™-B Group</arm_group_label>
    <other_name>DTPwcsl vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix™-B</intervention_name>
    <description>GSK Biologicals' hepatitis B vaccine</description>
    <arm_group_label>Triple Antigen™+Engerix™-B Group</arm_group_label>
    <other_name>HBV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for the Rotarix™ vaccine</description>
    <arm_group_label>Tritanrix™-HepB+Placebo Group</arm_group_label>
    <arm_group_label>Zilbrix™+Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subjects who the investigator believes that their parent/guardian can and will comply
             with the requirements of the protocol.

          -  Administration of one dose of hepatitis B vaccine at birth.

          -  A male or female between, and including, 11 and 17 weeks of age at the time of the
             first DTPw vaccination.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

        Exclusion criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             within 30 days before the first vaccine dose or planned administration during the
             study period with the exception of oral polio vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination (no laboratory testing is required)

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivanteevka Moscow region</city>
        <zip>141280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>129347</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Samara</city>
        <zip>443021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634 050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>December 20, 2016</results_first_submitted>
  <results_first_submitted_qc>April 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2017</results_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Hepatitis B diseases</keyword>
  <keyword>Tetanus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>104021</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104021</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104021</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104021</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104021</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104021</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tritanrix™-HepB+Rotarix™ Group</title>
          <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="P2">
          <title>Tritanrix™-HepB+Placebo Group</title>
          <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="P3">
          <title>Zilbrix™+Rotarix™ Group</title>
          <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="P4">
          <title>Zilbrix™+Placebo Group</title>
          <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="P5">
          <title>Triple Antigen™+Engerix™-B Group</title>
          <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tritanrix™-HepB+Rotarix™ Group</title>
          <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="B2">
          <title>Tritanrix™-HepB+Placebo Group</title>
          <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Zilbrix™+Rotarix™ Group</title>
          <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Zilbrix™+Placebo Group</title>
          <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Triple Antigen™+Engerix™-B Group</title>
          <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="99"/>
            <count group_id="B6" value="308"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.0" spread="1.70"/>
                    <measurement group_id="B2" value="13.4" spread="1.87"/>
                    <measurement group_id="B3" value="12.8" spread="1.39"/>
                    <measurement group_id="B4" value="12.8" spread="1.56"/>
                    <measurement group_id="B5" value="12.9" spread="1.33"/>
                    <measurement group_id="B6" value="12.93" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies</title>
        <description>Seroprotection status (SP) defined vaccinated subjects with antibody concentrations greater than or equal to (≥) 0.1 international units per millitre (IU/mL) as assessed by the Enzyme-linked Immunosorbent Assay (ELISA) or ≥ 0.016 IU/mL by neautralization assay on Vero cells in subjects seronegative for ELISA.</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis were performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies</title>
          <description>Seroprotection status (SP) defined vaccinated subjects with antibody concentrations greater than or equal to (≥) 0.1 international units per millitre (IU/mL) as assessed by the Enzyme-linked Immunosorbent Assay (ELISA) or ≥ 0.016 IU/mL by neautralization assay on Vero cells in subjects seronegative for ELISA.</description>
          <population>The analysis were performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.7" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="83.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="94.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O5" value="98.9" lower_limit="93.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects for Anti-DT Antibodies as Assessed by ELISA</title>
        <description>A seroprotected subject is a vaccinated subject with concentrations ≥ 0.1 IU/mL.</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for Anti-DT Antibodies as Assessed by ELISA</title>
          <description>A seroprotected subject is a vaccinated subject with concentrations ≥ 0.1 IU/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects for Anti-Hepatitis B (Anti-HBs) Antibodies</title>
        <description>A seroprotected subject was defined as a vaccinated subject with antibody concentrations ≥ 10 milli-international units per millilitre (mIU/mL).</description>
        <time_frame>At one most post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for Anti-Hepatitis B (Anti-HBs) Antibodies</title>
          <description>A seroprotected subject was defined as a vaccinated subject with antibody concentrations ≥ 10 milli-international units per millilitre (mIU/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects With Anti-Bordetella Pertussis (Anti-BPT) Antibody Concentrations ≥ the Established Cut-off Values</title>
        <description>A seropositive subject was defined as a subject with Anti-BPT antibody concentrations ≥ 15 ELISA units per millilitre (EL.U/mL), as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA).</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects With Anti-Bordetella Pertussis (Anti-BPT) Antibody Concentrations ≥ the Established Cut-off Values</title>
          <description>A seropositive subject was defined as a subject with Anti-BPT antibody concentrations ≥ 15 ELISA units per millilitre (EL.U/mL), as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Response to BPT Antigen</title>
        <description>Vaccine response (VR) was defined as the appearance of antibodies in subjects seronegative at pre-vaccination and antibody concentrations ≥ the cut-off values post-vaccination in subjects who were seropositive at pre-vaccination.</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Vaccine Response to BPT Antigen</title>
          <description>Vaccine response (VR) was defined as the appearance of antibodies in subjects seronegative at pre-vaccination and antibody concentrations ≥ the cut-off values post-vaccination in subjects who were seropositive at pre-vaccination.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects With Anti-rotavirus (Anti-RV) Antibodies Above the Cut-off Values</title>
        <description>A seropositive subject was defined as a subject with anti-RV antibody concentrations ≥ 20 units per millilitre (U/mL).</description>
        <time_frame>At 2.5 months after dose 2 of Rotarix [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects With Anti-rotavirus (Anti-RV) Antibodies Above the Cut-off Values</title>
          <description>A seropositive subject was defined as a subject with anti-RV antibody concentrations ≥ 20 units per millilitre (U/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects for Anti-Tetanus (Anti-T) Antigen</title>
        <description>A seroprotected subject was defined as a vaccinated subject with anti-T antibody concentrations ≥ the cut-off value of 0.1 international units per millilitre (IU/mL).</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for Anti-Tetanus (Anti-T) Antigen</title>
          <description>A seroprotected subject was defined as a vaccinated subject with anti-T antibody concentrations ≥ the cut-off value of 0.1 international units per millilitre (IU/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects for Anti-Poliovirus Types 1, 2, 3 (Anti-Polio 1, 2, 3)</title>
        <description>A seroprotected subject was defined as a vaccinated subject with anti-Polio type 1,2 ,3 antibody titers ≥ 8</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for Anti-Poliovirus Types 1, 2, 3 (Anti-Polio 1, 2, 3)</title>
          <description>A seroprotected subject was defined as a vaccinated subject with anti-Polio type 1,2 ,3 antibody titers ≥ 8</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1, [N=54,17,47,14,72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, [N=58,18,57,14,79]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, [N=57,18,55,15,79]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Anti-HBs Antibodies</title>
        <description>Concentrations of anti-HB, antibodies, expressed as Geometric Mean Concentrations (GMCs), were measured in mIU/mL.</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Anti-HBs Antibodies</title>
          <description>Concentrations of anti-HB, antibodies, expressed as Geometric Mean Concentrations (GMCs), were measured in mIU/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600.5" lower_limit="473.1" upper_limit="762.3"/>
                    <measurement group_id="O2" value="732.7" lower_limit="472.0" upper_limit="1137.3"/>
                    <measurement group_id="O3" value="789.8" lower_limit="626.8" upper_limit="995.1"/>
                    <measurement group_id="O4" value="850.6" lower_limit="527.7" upper_limit="1371.2"/>
                    <measurement group_id="O5" value="578.6" lower_limit="442.3" upper_limit="757.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Anti-DT Antibodies</title>
        <description>Concentrations of anti-DT antibodies, expressed as Geometric Mean Concentrations (GMCs), were measured in IU/mL.</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Anti-DT Antibodies</title>
          <description>Concentrations of anti-DT antibodies, expressed as Geometric Mean Concentrations (GMCs), were measured in IU/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.667" lower_limit="0.517" upper_limit="0.862"/>
                    <measurement group_id="O2" value="0.545" lower_limit="0.276" upper_limit="1.078"/>
                    <measurement group_id="O3" value="0.957" lower_limit="0.725" upper_limit="1.262"/>
                    <measurement group_id="O4" value="0.906" lower_limit="0.569" upper_limit="1.444"/>
                    <measurement group_id="O5" value="1.096" lower_limit="0.869" upper_limit="1.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Anti-T Antibodies</title>
        <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in international units per millillitre (IU/mL).</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Anti-T Antibodies</title>
          <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in international units per millillitre (IU/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.138" lower_limit="2.580" upper_limit="3.817"/>
                    <measurement group_id="O2" value="3.350" lower_limit="2.173" upper_limit="5.164"/>
                    <measurement group_id="O3" value="3.737" lower_limit="3.079" upper_limit="4.535"/>
                    <measurement group_id="O4" value="5.323" lower_limit="3.411" upper_limit="8.306"/>
                    <measurement group_id="O5" value="3.319" lower_limit="2.838" upper_limit="3.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Anti-BPT Antibodies</title>
        <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in EL.U/mL.</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Anti-BPT Antibodies</title>
          <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in EL.U/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" lower_limit="57.9" upper_limit="74.5"/>
                    <measurement group_id="O2" value="50.8" lower_limit="36.5" upper_limit="70.6"/>
                    <measurement group_id="O3" value="40.1" lower_limit="33.8" upper_limit="47.5"/>
                    <measurement group_id="O4" value="37.2" lower_limit="25.6" upper_limit="54.3"/>
                    <measurement group_id="O5" value="38.0" lower_limit="32.5" upper_limit="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Anti-RV Antibodies</title>
        <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in U/mL.</description>
        <time_frame>At 2.5 months post dose 2 of Rotarix [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.lysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Anti-RV Antibodies</title>
          <description>Concentrations, expressed as Geometric Mean Concentrations (GMCs), were measured in U/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.lysis</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="57.5" upper_limit="161.8"/>
                    <measurement group_id="O2" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                    <measurement group_id="O3" value="93.1" lower_limit="56.1" upper_limit="154.3"/>
                    <measurement group_id="O4" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Polio Type 1, 2, 3 Antibody Titers</title>
        <description>Anti-Polio type 1, 2 and 3 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
        <time_frame>At one month post dose 3 [PIII(M4)]</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Polio Type 1, 2, 3 Antibody Titers</title>
          <description>Anti-Polio type 1, 2 and 3 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects (i.e. those who met all eligibility criteria, complied with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning immunogenicity measures were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1, [N=54,17,47,14,72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="900.7" lower_limit="643.1" upper_limit="1261.5"/>
                    <measurement group_id="O2" value="1181.0" lower_limit="604.4" upper_limit="2307.7"/>
                    <measurement group_id="O3" value="877.7" lower_limit="612.3" upper_limit="1257.9"/>
                    <measurement group_id="O4" value="779.9" lower_limit="391.3" upper_limit="1554.1"/>
                    <measurement group_id="O5" value="1155.0" lower_limit="877.8" upper_limit="1519.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, [N=58,18,57,14,79]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="811.2" lower_limit="655.3" upper_limit="1004.1"/>
                    <measurement group_id="O2" value="1024.0" lower_limit="679.8" upper_limit="1542.2"/>
                    <measurement group_id="O3" value="774.2" lower_limit="602.4" upper_limit="994.9"/>
                    <measurement group_id="O4" value="882.6" lower_limit="538.2" upper_limit="1447.4"/>
                    <measurement group_id="O5" value="825.9" lower_limit="661.7" upper_limit="1031.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, [N=57,18,55,15,79]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326.6" lower_limit="234.7" upper_limit="454.3"/>
                    <measurement group_id="O2" value="369.1" lower_limit="163.6" upper_limit="832.8"/>
                    <measurement group_id="O3" value="313.3" lower_limit="240.8" upper_limit="407.7"/>
                    <measurement group_id="O4" value="330.3" lower_limit="185.4" upper_limit="588.4"/>
                    <measurement group_id="O5" value="351.3" lower_limit="267.5" upper_limit="461.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms</title>
        <description>Solicited local symptoms were pain, redness and swelling. Any = occurence of symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest, pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling with a maximum diameter greater than 30 millimeters (mm).</description>
        <time_frame>During the 8-Day (Days 0-7) follow-up period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms</title>
          <description>Solicited local symptoms were pain, redness and swelling. Any = occurence of symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest, pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling with a maximum diameter greater than 30 millimeters (mm).</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1 [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1 [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1 [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1 [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1 [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1 [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 3 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 3 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 3 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 3 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 3 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 3 [N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Across [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Across [N=78;25;76;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were diarrhea, drowsiness, fever [defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)], irritability, loss of appetite [loss of appet.] and vomiting. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. Grade 3 loss of appetite = symptoms that prevents eating. Grade 3 diarrhea = ≥ 6 looser than normal stools per (/) day. Grade 3 vomiting = ≥ 3 episodes of vomiting/day.</description>
        <time_frame>During the 8-day period (Days 0-7) post-vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were diarrhea, drowsiness, fever [defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)], irritability, loss of appetite [loss of appet.] and vomiting. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. Grade 3 loss of appetite = symptoms that prevents eating. Grade 3 diarrhea = ≥ 6 looser than normal stools per (/) day. Grade 3 vomiting = ≥ 3 episodes of vomiting/day.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Diarrhea, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Diarrhea, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Diarrhea, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appet., Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appet., Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appet., Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Vomiting, Dose 1[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Diarrhea, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Diarrhea, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Diarrhea, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appet., Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appet., Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appet., Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Vomiting, Dose 2[N=76;25;75;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Diarrhea, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Diarrhea, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Diarrhea, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appet., Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appet., Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appet., Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Vomiting, Dose 3[N=76;25;73;22;96]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Diarrhea, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Diarrhea, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Diarrhea, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appet., Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appet., Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appet., Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Vomiting, Across[N=78;25;77;23;98]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>Number of subjects with any unsolicited adverse events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>During the 31-day (Days 0-30) follow-up period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>Number of subjects with any unsolicited adverse events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Month 0 to Month 4</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Tritanrix™-HepB+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix™-HepB+Placebo Group</title>
            <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Zilbrix™+Rotarix™ Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Zilbrix™+Placebo Group</title>
            <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Triple Antigen™+Engerix™-B Group</title>
            <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local+general during the 8-day (Days 0-7) post vaccination; AEs within the 31-Day;SAEs up to study end at Month 4</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tritanrix™-HepB+Rotarix™ Group</title>
          <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="E2">
          <title>Tritanrix™-HepB+Placebo Group</title>
          <description>Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="E3">
          <title>Zilbrix™+Rotarix™ Group</title>
          <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="E4">
          <title>Zilbrix™+Placebo Group</title>
          <description>Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.</description>
        </group>
        <group group_id="E5">
          <title>Triple Antigen™+Engerix™-B Group</title>
          <description>Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Laryngotracheitis obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Overgrowth bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="68" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="80" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

